Patients

Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?

Amplifying the Patient's Voice with Real-World Evidence

Discover the three essential steps for optimizing the quality and reliability of demand research.

The first wave of Ipsos’s Syndicated Global RSV study, fielded in 8 markets in Europe.

After decades of failed attempts, the respiratory syncytial virus (RSV) treatment and vaccine landscape is on the verge of profound change.

Understanding why real-world treatment in oncology can be sub-optimal – and what can be done about it.

As the healthcare sector evolves at speed, pharma needs an improved framework to guide its marketing effort and answer the eternal business questions: who to target and how.

The Untenable Journey

Momentum continues to build in the use of high-efficacy, disease modifying therapies (DMTs) as a first choice for treating multiple sclerosis. How is this being influenced by the availability of anti-CD20s, a new class of DMT? Will future new therapy classes change the paradigm even further?